SEARCH

SEARCH BY CITATION

References

  • Blanchard V., Anglade P., Dziewczapolski G., Savasta M., Agid Y. and Raisman-Vozari R. (1996) Dopaminergic sprouting in the rat striatum after partial lesion of the substantia nigra. Brain Res. 709, 319325.
  • Campbell K. and Bjorklund A. (1995) Neurotransmitter-related gene expression in intrastriatal striatal transplants. III. Regulation by host cortical and dopaminergic afferents. Brain Res. Mol. Brain Res. 29, 263272.
  • Cenci M. A. (2007) Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia. Trends Neurosci. 30, 236243.
  • Cenci M. A. and Lundblad M. (2006) Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia. J. Neurochem. 99, 381392.
  • Chung C. Y., Seo H., Sonntag K. C., Brooks A., Lin L. and Isacson O. (2005) Cell type-specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protection. Human Mol. Genet. 14, 17091725.
  • Datla K. P., Blunt S. B. and Dexter D. T. (2001) Chronic L-DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6-OHDA or FeCl(3) nigrostriatal lesions. Mov. Disord. 16, 424434.
  • Debeir T., Ginestet L., Francois C., Laurens S., Martel J. C., Chopin P., Marien M., Colpaert F. and Raisman-Vozari R. (2005) Effect of intrastriatal 6-OHDA lesion on dopaminergic innervation of the rat cortex and globus pallidus. Exp. Neurol. 193, 444454.
  • Deuel T. F., Zhang N., Yeh H.-J., Silos-Santiago I. and Wang Z.-Y. (2002) Pleiotrophin: a cytokine with diverse functions and a novel signaling pathway. Arch. Biochem. Biophys. 397, 162171.
  • Dobbertin A., Rhodes K. E., Garwood J., Properzi F., Heck N., Rogers J. H., Fawcett J. W. and Faissner A. (2003) Regulation of RPTPbeta/phosphacan expression and glycosaminoglycan epitopes in injured brain and cytokine-treated glia. Mol. Cell. Neurosci. 24, 951971.
  • Dunah A. W., Sirianni A. C., Fienberg A. A., Bastia E., Schwarzschild M. A. and Standaert D. G. (2004) Dopamine D1-dependent trafficking of striatal N-methyl-d-aspartate glutamate receptors requires Fyn protein tyrosine kinase but not DARPP-32. Mol. Pharmacol. 65, 121129.
  • Ferrario J. E., Delfino M. A., Stefano A. V., Zbarsky V., Douhou A., Murer M. G., Raisman-Vozari R. and Gershanik O. S. (2003) Effects of orally administered levodopa on mesencephalic dopaminergic neurons undergoing a degenerative process. Neurosci. Res. 47, 431436.
  • Ferrario J. E., Taravini I. R., Mourlevat S., Stefano A., Delfino M. A., Raisman-Vozari R., Murer M. G., Ruberg M. and Gershanik O. (2004) Differential gene expression induced by chronic levodopa treatment in the striatum of rats with lesions of the nigrostriatal system. J. Neurochem. 90, 13481358.
  • Finkelstein D. I., Stanic D., Parish C. L., Tomas D., Dickson K. and Horne M. K. (2000) Axonal sprouting following lesions of the rat substantia nigra. Neuroscience 97, 99112.
  • Fujikawa A., Chow J. P., Shimizu H., Fukada M., Suzuki R. and Noda M. (2007) Tyrosine phosphorylation of ERBB4 is enhanced by PSD95 and repressed by protein tyrosine phosphatase receptor type Z. J. Biochem. (Tokyo) 142, 343350.
  • Gu W. H., Yang S., Shi W. X., Jin G. Z. and Zhen X. C. (2007) Requirement of PSD-95 for dopamine D1 receptor modulating glutamate NR1a/NR2B receptor function. Acta Pharmacol. Sin. 28, 756762.
  • Hayashi N., Oohira A. and Miyata S. (2005) Synaptic localization of receptor-type protein tyrosine phosphatase zeta/beta in the cerebral and hippocampal neurons of adult rats. Brain Res. 1050, 163169.
  • Hellemans J., Mortier G., De Paepe A., Speleman F. and Vandesompele J. (2007) qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data. Genome Biol. 8, R19.
  • Hida H., Jung C. G., Wu C. Z., Kim H. J., Kodama Y., Masuda T. and Nishino H. (2003) Pleiotrophin exhibits a trophic effect on survival of dopaminergic neurons in vitro. Eur. J. Neurosci. 17, 21272134.
  • Hida H., Masuda T., Sato T., Kim T. S., Misumi S. and Nishino H. (2007) Pleiotrophin promotes functional recovery after neural transplantation in rats. Neuroreport 18, 179183.
  • Hirsch E. C. (2000) Nigrostriatal system plasticity in Parkinson’s disease: effect of dopaminergic denervation and treatment. Ann. Neurol. 47, S115S120; discussion: S120–121.
  • Johnson K. G. and Van Vactor D. (2003) Receptor protein tyrosine phosphatases in nervous system development. Physiol. Rev. 83, 124.
  • Jung C. G., Hida H., Nakahira K., Ikenaka K., Kim H. J. and Nishino H. (2004) Pleiotrophin mRNA is highly expressed in neural stem (progenitor) cells of mouse ventral mesencephalon and the product promotes production of dopaminergic neurons from embryonic stem cell-derived nestin-positive cells. FASEB J. 18, 12371239.
  • Kastner A., Hirsch E. C., Agid Y. and Javoy-Agid F. (1993) Tyrosine hydroxylase protein and messenger RNA in the dopaminergic nigral neurons of patients with Parkinson’s disease. Brain Res. 606, 341345.
  • Kawachi H., Tamura H., Watakabe I., Shintani T., Maeda N. and Noda M. (1999) Protein tyrosine phosphatase zeta/RPTPbeta interacts with PSD-95/SAP90 family. Brain Res. Mol. Brain Res. 72, 4754.
  • Lauri S. E., Taira T., Kaila K. and Rauvala H. (1996) Activity-induced enhancement of HB-GAM expression in rat hippocampal slices. Neuroreport 7, 16701674.
  • Levy J. B., Canoll P. D., Silvennoinen O. et al. (1993) The cloning of a receptor-type protein tyrosine phosphatase expressed in the central nervous system. J. Biol. Chem. 268, 1057310581.
  • Maeda N., Nishiwaki T., Shintani T., Hamanaka H. and Noda M. (1996) 6B4 proteoglycan/phosphacan, an extracellular variant of receptor-like protein-tyrosine phosphatase zeta/RPTPbeta, binds pleiotrophin/heparin-binding growth-associated molecule (HB-GAM). J. Biol. Chem. 271, 2144621452.
  • Marchionini D. M., Lehrmann E., Chu Y., He B., Sortwell C. E., Becker K. G., Freed W. J., Kordower J. H. and Collier T. J. (2007) Role of heparin binding growth factors in nigrostriatal dopamine system development and Parkinson’s disease. Brain Res. 1147, 7788.
  • Meng K., Rodriguez-Pena A., Dimitrov T., Chen W., Yamin M., Noda M. and Deuel T. F. (2000) Pleiotrophin signals increased tyrosine phosphorylation of beta beta-catenin through inactivation of the intrinsic catalytic activity of the receptor-type protein tyrosine phosphatase beta/zeta. Proc. Natl Acad. Sci. USA 97, 26032608.
  • Mourlevat S., Debeir T., Ferrario J. E., Delbe J., Caruelle D., Lejeune O., Depienne C., Courty J., Raisman-Vozari R. and Ruberg M. (2005) Pleiotrophin mediates the neurotrophic effect of cyclic AMP on dopaminergic neurons: analysis of suppression-subtracted cDNA libraries and confirmation in vitro. Exp. Neurol. 194, 243254.
  • Murer M. G., Dziewczapolski G., Menalled L. B., Garcia M. C., Agid Y., Gershanik O. and Raisman-Vozari R. (1998) Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann. Neurol. 43, 561575.
  • Pariser H., Perez-Pinera P., Ezquerra L., Herradon G. and Deuel T. F. (2005a) Pleiotrophin stimulates tyrosine phosphorylation of beta-adducin through inactivation of the transmembrane receptor protein tyrosine phosphatase beta/zeta. Biochem. Biophys. Res. Commun. 335, 232239.
  • Pariser H., Ezquerra L., Herradon G., Perez-Pinera P. and Deuel T. F. (2005b) Fyn is a downstream target of the pleiotrophin/receptor protein tyrosine phosphatase beta/zeta-signaling pathway: regulation of tyrosine phosphorylation of Fyn by pleiotrophin. Biochem. Biophys. Res. Commun. 332, 664669.
  • Paxinos G. and Watson C. (1986) The Rat Brain in Stereotaxic Coordinates, 2nd Edn. Academic Press, Sydney, Australia.
  • Poulsen F. R., Lagord C., Courty J., Pedersen E. B., Barritault D. and Finsen B. (2000) Increased synthesis of heparin affin regulatory peptide in the perforant path lesioned mouse hippocampal formation. Exp. Brain Res. 135, 319330.
  • Raisman-Vozari R., Girault J. A., Moussaoui S., Feuerstein C., Jenner P., Marsden C. D. and Agid Y. (1990) Lack of change in striatal DARPP-32 levels following nigrostriatal dopaminergic lesions in animals and in parkinsonian syndromes in man. Brain Res. 507, 4550.
  • Rasband W. S. (19972007) ImageJ. US National Institutes of Health, Bethesda, Maryland, USA. http://rsb.info.nih.gov/ij/ .
  • Raulo E., Chernousov M. A., Carey D. J., Nolo R. and Rauvala H. (1994) Isolation of a neuronal cell surface receptor of heparin binding growth-associated molecule (HB-GAM). Identification as N-syndecan (syndecan-3). J. Biol. Chem. 269, 1299913004.
  • Rauvala H. and Peng H. B. (1997) HB-GAM (heparin-binding growth-associated molecule) and heparin-type glycans in the development and plasticity of neuron-target contacts. Prog. Neurobiol. 52, 127144.
  • Stoica G. E., Kuo A., Aigner A. et al. (2001) Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin. J. Biol. Chem. 276, 1677216779.
  • Takeda A., Onodera H., Sugimoto A., Itoyama Y., Kogure K., Rauvala H. and Shibahara S. (1995) Induction of heparin-binding growth-associated molecule expression in reactive astrocytes following hippocampal neuronal injury. Neuroscience 68, 5764.
  • Taravini I. R., Ferrario J. E., Delbe J., Ginestet L., Debeir T., Courty J., Murer M. G., Gershanik O. S. and Raisman-Vozari R. (2005) Immunodetection of heparin-binding growth associated molecule (pleiotrophin) in striatal interneurons. Brain Res. 1066, 196200.
  • Vandesompele J., De Preter K., Pattyn F., Poppe B., Van Roy N., De Paepe A. and Speleman F. (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 3, RESEARCH0034.
  • Wanaka A., Carroll S. L. and Milbrandt J. (1993) Developmentally regulated expression of pleiotrophin, a novel heparin binding growth factor, in the nervous system of the rat. Brain Res. Dev. Brain Res. 72, 133144.
  • Westin J. E., Lindgren H. S., Gardi J., Nyengaard J. R., Brundin P., Mohapel P. and Cenci M. A. (2006) Endothelial proliferation and increased blood-brain barrier permeability in the basal ganglia in a rat model of 3,4-dihydroxyphenyl-l-alanine-induced dyskinesia. J. Neurosci. 26, 94489461.
  • Zhang J., Vinuela A., Neely M. H., Hallett P. J., Grant S. G., Miller G. M., Isacson O., Caron M. G. and Yao W. D. (2007) Inhibition of the dopamine D1 receptor signaling by PSD-95. J. Biol. Chem. 282, 1577815789.